ImmunoGen

NEW YORK (GenomeWeb) – Roche's Ventana Medical Systems today announced a deal with ImmunoGen to develop an immunohistochemistry-based companion diagnostic test for the oncology therapeutic firm's product candidates.

Myriad, BioMarin Ink Deal to Use HRD Test to ID Responders to PARP Inhibitor

Genomind Introduces Physician Portal for Genecept Results

The US Food and Drug Administration last week approved Roche/Genentech's latest HER2-targeting breast cancer drug, trastuzumab emtansine (T-DM1).

Biotechnology firms participating in the Alzheimer's Disease Neuroimaging Initiative have received plasma and CSF samples from ADNI participants and contributed funds for the processing of roughly 1,000 samples by biomarker discovery firm Rules-Based Medicine.

People in the News

Premium

Peter Williams

BioRegion Real Estate

Premium

Massachusetts Biotechnology Council-BioReady Communities Campaign, Alkermes Relocation, Science + Technology Park at Johns Hopkins, Ohio State University Wright Center of Innovation in Biomedical Imaging, Londonderry Clinical Translational Research and Innovation Centre, Aeras Global TB Vaccine Foundation, BioBusiness Park at Elk Run, Chrysler-University of Delaware, ICON- Qualia Clinical Services

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.